Bad Homburg, Germany – September 25, 2026 -- Fresenius Medical Care will exit its peritoneal dialysis business in China and discontinue local production and sales of its 4008A hemodialysis system, triggering one-time costs of approximately €110 million in the third quarter of 2026.
The charge, tied to impairment, scrappage and termination costs, will be treated as a special item and is not expected to meaningfully affect the future revenue outlook for the China business within the Company's Care Enablement segment.
China accounts for 6-7% of Care Enablement segment revenue
Fresenius Medical Care has operated in China for more than two decades, a market the Company says offers long-term growth tied to rising chronic kidney disease prevalence and expanding dialysis care.
Company narrows portfolio toward advanced in-center dialysis technology
Going forward, Fresenius Medical Care will concentrate on in-center dialysis and critical care products, including the hemodiafiltration-enabled 5008S CAREsystem and the multiFiltratePRO platform, while maintaining existing obligations to patients affected by the PD exit.
"China is an important market for our Care Enablement business," said Helen Giza, Chief Executive Officer for Fresenius Medical Care. "As the market evolves, we are refining our portfolio to focus on the areas where we can create the greatest value for patients and customers."
Rex Liu appointed China General Manager as leadership is localized
The Company has strengthened local leadership with the appointment of Rex Liu as market General Manager, part of a broader push toward a localized portfolio and commercialization of China-relevant innovation.
Joe Turk, CEO of Fresenius Medical Care's Care Enablement segment, said the Company will continue leveraging its local manufacturing footprint and China Design Center to pursue profitable growth in the market.